Aurobindo Pharma is trading higher by 2.4% at Rs 317, extending its Friday’s 4% rally, after said it has received the final approval from the U.S. health regulator to manufacture and market Duloxetine Hydrochloride Delayed-Release capsules, an anti-depressant drug, in the American market.
“The market size of the product is estimated to be $5.4 billion for the twelve months ending September 2013,” Aurobindo Pharma said in a regulatory filing.
The company has a total of 188 Abbreviated New Drug Application (ANDA) approvals from USFDA, of which 163 are final approvals and 25 are tentative approvals, it added.
The stock opened at Rs 310 and touched high of Rs 319, also its 52-week high on the BSE. A combined around one million shares have changed hands on the counter till 0942 hours on the BSE and NSE.
“The market size of the product is estimated to be $5.4 billion for the twelve months ending September 2013,” Aurobindo Pharma said in a regulatory filing.
The company has a total of 188 Abbreviated New Drug Application (ANDA) approvals from USFDA, of which 163 are final approvals and 25 are tentative approvals, it added.
The stock opened at Rs 310 and touched high of Rs 319, also its 52-week high on the BSE. A combined around one million shares have changed hands on the counter till 0942 hours on the BSE and NSE.